Author Archives: Steph

November 14, 2019
In The News

Molecule prospector Atomwise co-founded a drug research company alongside Velocity Pharmaceutical Development designed to shepherd its artificial intelligence-derived candidates through preclinical testing and into potential takeout deals with pharma industry partners. Dubbed X-37, the new firm will maintain a flexible LLC structure that will house each development program within its own virtual subcompany. This will […]

Read Article
June 3, 2019
Press Release

Atomwise Inc. today announced a multi-year agreement with Eli Lilly and Company to apply Atomwise’s patented artificial intelligence (AI) technology in support of Lilly’s preclinical drug discovery efforts. The companies will collaborate on up to ten drug targets selected by Lilly, with the goal of accelerating the time it takes to identify and develop potential […]

Read Article
May 2, 2019
In The News

Originally published on the YC Blog on April 29, 2019. By Jared Friedman In the last 10 years, the tools for studying biology have become much less expensive and more widely available. This has made it possible for new startups to do serious research right from the start, and it is leading to an explosion […]

Read Article
January 11, 2019
Press Release

Charles River reaffirms commitment to the future of drug discovery by advancing the Company’s integrated, innovative early-stage platform WILMINGTON, Mass., and SAN FRANCISCO, Calif., January 11, 2019 – Charles River Laboratories International, Inc. (NYSE: CRL) and Atomwise, Inc. today announced the formation of a strategic alliance that offers clients access to Atomwise’s artificial intelligence (AI)-powered, […]

Read Article
January 11, 2019
Press Release

Charles River’s clients gain access to Atomwise’s Artificial Intelligence (AI) technology to improve novelty, quality and efficiency of preclinical drug discovery. SAN FRANCISCO, January 11, 2019 – Atomwise, Inc. today announced a strategic alliance with Charles River Laboratories International, Inc., which will offer biotech and pharmaceutical companies an end-to-end drug discovery solution that unites AI […]

Read Article